Applied DNA reports positive preclinical results for COVID-19 vaccine
Applied DNA Sciences Inc. (APDN) announced that its COVID-19 vaccine candidate has yielded robust antibody and T-cell responses even at very low doses of linear DNA. The company is collaborating with Takis Biotech for developing this vaccine. Both the companies believe that no single vaccine may be able to offer a universal solution to the outbreak.
During the trial, BALB/c mice were given linear DNA at day 1 and a booster vaccination on day 21. All animals exhibited seroconversion to producing IgG against SARS-CoV-2